Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness,…
Scaling Smart: Strengthen Systems Before Expanding
ECCA and TTEC Release “Visionary Voices” Research on the Future of Contact Centre Sales in Europe